Review
Open access
Oct 2026
Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular–Kidney–Metabolic Disease: A Narrative Review
HTD1801 has demonstrated multidomain metabolic and hepatic activity, but direct human evidence supporting its use with other CKM therapies remains limited and is currently established only for metformin.
B. Kim, Joseph Kim, Grace Kim et al.
· Pharmaceuticals · 0 citations